Suppr超能文献

长期体外扩增人脂肪来源干细胞显示出较低的致瘤风险。

Long-term in vitro expansion of human adipose-derived stem cells showed low risk of tumourigenicity.

机构信息

Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

出版信息

J Tissue Eng Regen Med. 2014 Jan;8(1):67-76. doi: 10.1002/term.1501. Epub 2012 May 2.

Abstract

In the field of cell-based therapy and regenerative medicine, clinical application is the ultimate goal. However, one major concern is: does in vitro manipulation during culture expansion increases tumourigenicity risk on the prepared cells? Therefore, the aim of this study was to investigate the effect of long-term in vitro expansion on human adipose-derived stem cells (ASCs). The ASCs were harvested from lipo-aspirate samples and cultured until passage 20 (P20), using standard culture procedures. ASCs at P5, P10, P15 and P20 were analysed for morphological changes, DNA damage (Comet assay), tumour suppressor gene expression level (quantitative PCR), p53 mutation, telomerase activity, telomere length determination and in vivo tumourigenicity test. Our data showed that ASCs lost their fibroblastic feature in long-term culture. The population doubling time of ASCs increased with long-term culture especially at P15 and P20. There was an increase in DNA damage at later passages (P15 and P20). No significant changes were observed in both p53 and p21 genes expression throughout the long-term culture. There was also no p53 mutation detected and no significant changes were recorded in the relative telomerase activity (RTA) and mean telomere length (TRF) in ASCs at all passages. In vivo implantation of ASCs at P15 and P20 into the nude mice did not result in tumour formation after 4 months. The data showed that ASCs have low risk of tumourigenicity up to P20, with a total population doubling of 42 times. This indicates that adipose tissue should be a safe source of stem cells for cell-based therapy.

摘要

在细胞治疗和再生医学领域,临床应用是最终目标。然而,一个主要关注的问题是:在培养扩增过程中的体外操作是否会增加制备细胞的致瘤风险?因此,本研究旨在探讨长期体外扩增对人脂肪来源干细胞(ASCs)的影响。使用标准培养程序,从脂肪抽吸样本中收获 ASCs 并培养至第 20 代(P20)。分析第 5、10、15 和 20 代的 ASCs 的形态变化、DNA 损伤(彗星试验)、肿瘤抑制基因表达水平(定量 PCR)、p53 突变、端粒酶活性、端粒长度测定和体内致瘤性试验。我们的数据显示,ASCs 在长期培养中失去了成纤维细胞特征。ASCs 的群体倍增时间随着长期培养而增加,尤其是在 P15 和 P20。晚期传代(P15 和 P20)时 DNA 损伤增加。整个长期培养过程中,p53 和 p21 基因表达均无明显变化。未检测到 p53 突变,所有传代的相对端粒酶活性(RTA)和平均端粒长度(TRF)也无明显变化。将 P15 和 P20 代的 ASCs 植入裸鼠体内 4 个月后,未形成肿瘤。数据表明,ASCs 至 P20 代的致瘤风险较低,总群体倍增为 42 倍。这表明脂肪组织应该是细胞治疗的安全干细胞来源。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验